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Background: The ubiquitous use of dibutyl phthalate (DBP), one of the most widely used plasticizers, results in
extensive exposure to humans and the environment. DBP and its major metabolite, monobutyl phthalate (MBP),
may alter steroid biosynthesis and their exposure may lead to damage to male reproductive function. Low-doses of
DBP/MBP may result in increased steroidogenesis in vitro and in vivo. However, the mechanisms of possible effects
of low-dose MBP on steroidogenesis remain unclear. The aim of present study was to elaborate the role of
transcription factors and steroidogenic acute regulatory protein in low-dose MBP-induced distruption of
steroidogenesis in mouse Leydig tumor cells (MLTC-1 cells).
Methods: In the present study, MLTC-1 cells were cultured in RPMI 1640 medium supplemented with 2 g/L sodium
bicarbonate. Progesterone level was examined by I125-pregesterone Coat-A-Count radioimmunoassay (RIA) kits.
mRNA and protein levels were assessed by reverse transcription-polymerase chain reaction (RT-PCR) and western
blot, respectively. DNA-binding of several transcription factors was examined by electrophoretic mobility shift
assay (EMSA).
Results: In this study, various doses of MBP (0, 10(−9), 10(−8), 10(−7), or 10(−6) M) were added to the medium
followed by stimulation of MLTC-1 cells with human chorionic gonadotrophin (hCG). The results showed that MBP
increased progesterone production and steroidogenic acute regulatory protein (StAR) mRNA and protein levels.
However, the protein levels of cytochrome P450scc and 3 beta-hydroxy-steroid dehydrogenase (3 beta-HSD) were
unchanged after MBP treatment. EMSA assay showed that DNA-binding of steroidogenic factors 1(SF-1), GATA-4
and CCAAT/enhancer binding protein-beta (C/EBP-beta) was increased in a dose-dependent manner after MBP
exposure. Western blot tests were next employed and confirmed that the protein levels of SF-1, GATA-4 and
C/EBP-beta were also increased. Additionally, western blot tests confirmed the expression of DAX-1, negative factor
of SF-1, was dose-dependently down regulated after MBP exposure, which further confirmed the role of SF-1 in
MBP-stimulated steroid biosynthesis.
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Conclusions: In conclusion, we firstly delineated the regulation of StAR by transcription factors including SF-1, GATA-4
and C/EBP-beta maybe critical mechanism involved in low-dose MBP-stimulated steroidogenesis.
Keywords: Monobutyl phthalate, Progesterone, Steroidogenic acute regulatory protein, Steroidogenic factors 1,
GATA-4, CCAAT/enhancer binding protein-beta, Mouse Leydig tumor cellsBackground
Phthalates (PAEs) are ubiquitous in environmental media
and human bodies [1]. They are used as plasticizers in
polyvinyl chloride plastics that make consumer products
such as flexible plastic and toys, curtains, wallpaper, food
packaging, plastic wrap and medical devices [2]. PAEs can
diffuse to the environment easily, and humans are exposed
to PAEs through ingestion, inhalation, and dermal expo-
sure [3].
Dibutyl phthalate (DBP) is one of the most commonly
used PAEs in polyvinyl chloride products, which is
widely detectable in milk, blood and urine in the general
population [4,5]. DBP may exert adverse anti-androgenic
effects and its exposure may lead to damage to male
reproductive function, such as morphological changes in
sperm, shortened anogenital distance (AGD) which is a
marker of feminisation in male infants [6-8]. Further-
more, previous studies revealed that administration of
DBP to male mammals during sexual differentiation
resulted in malformations in male offspring including
altered testicular weight, and altered testosterone levels
[9-11]. DBP and its active metabolite, monobutyl phtha-
late (MBP), have been proven to have no androgen
receptor binding in transcritional activation assays [12].
So, DBP/MBP may cause adverse anti-androgenic effects
though impairing testosterone synthesis [13,14]. Whereas
these results revealed the important effects of DBP/MBP
on steroidogenesis, all these results were obtained from
high administrations of DBP or MBP, usually 500 mg/kg
body weight per day or more which were higher than
the published data of human exposure (maximal level:
113 μg/kg body weight per day) [15,16].
It is estimated that human exposure to DBP ranging
from 0.84 to 113 μg/kg body weight per day [15]. Thus,
chronic exposure of humans to low doses of DBP is
ubiquitous. Some studies have focused on the effect of
low-dose of DBP/MBP on steroidogenesis (Fan J, et al.
2010. Endocrinology 151 3348–62) [17,18]. In these stud-
ies, relatively low doses of DBP/MBP resulted in increased
steroidogenesis in vitro and in vivo. Nonetheless, the
underlying mechanisms of possible effects of low-dose
MBP on steroidogenesis remain unclear.
In the steroid biosynthesis pathway, steroidogenic
acute regulatory protein (StAR) is a key protein and
plays an essential role in the delivery of cholesterol to
mitochondria which is considered as the rate-limitingstep in steroid biosynthesis [19,20]. Moreover, previous
studies also indicates that transcription factors exert
important roles in regulation of StAR expression, includ-
ing steroidogenic factors 1 (SF-1) [21-23], CCAAT/en-
hancer binding protein-beta (C/EBP-beta) [24,25], and
GATA-4 [23,25].
The cell line of mouse Leydig tumor cells (MLTC-1
cells) is an established mouse Leydig cell line, and is able
to synthesize progesterone as the major steroid in
response to human chorionic gonadotrophin (hCG). The
MLTC-1 cell line also keeps the consistent gonadotropin-
response compared with the primary Leydig cell line
before progesterone synthesis. Therefore, in this study, in
order to provide mechanistic insight into low-dose MBP-
induced distruption of steroidogenesis, we focused on
expression of StAR and the regulation of transcription
factors including SF-1, GATA-4 and C/EBP-beta on




MBP was purchased from Tokyo Kasei Kogyo Co., Ltd.
(Tokyo, Japan). Human Chorionic Gonadotropin (hCG),
bovine serum albumin (BSA), dimethyl sulfoxide
(DMSO), sodium dodecyl sulfate (SDS), diethylpyrocar-
bonate (DEPC), and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) were obtained
from Sigma-Aldrich (St. Louis, MO, USA). Fetal bovine
serum (FBS), RPMI 1640 medium, streptomycin sulfate,
antibiotic penicillin G sodium (10,000 U/mL) and phos-
phate-buffered saline with Ca2+ and Mg2+ (PBS+) were
obtained from Gibco BRL (Grand Island, NY, USA).
Reagents for real-time reverse transcription polymerase
chain reaction (RT-PCR) were obtained from Invitrogen
Life Technologies (Carlsbad, CA). All other chemicals
used were of analytical grade.
Cell culture and treatments
MLTC-1 cells were obtained from Cell Institute of
Shanghai, Chinese Academy of Sciences (Shanghai, China)
and maintained in RPMI 1640 medium supplemented
with 2 g/L sodium bicarbonate, 100 U/mL penicillin,
100 μg/mL streptomycin sulfate, and 10% fetal bovine
serum (FBS, pH 7.2). Cells were cultured in a humidified
atmosphere containing 95% air and 5% CO2 at 37°C.
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every 1 or 2 days.
MLTC-1 cells were seeded into 24-well plates at
concentration of 1×105 cells/mL in 1 mL of medium per
well for progesterone measurement as this cell line
produces progesterone as the major steroid in response
to trophic hormones [26]. After preincubated for 24 h,
the medium was removed and the cells were washed
twice with PBS+. MBP was firstly dissolved in DMSO
and then adjusted to a concentration of 10-3 M with
serum-free RPMI 1640 medium as stock solution. Cells
were treated with MBP at concentrations of 0, 10(−9),
10(−8), 10(−7), or 10(−6) M or its solvent DMSO for
24 h. The final concentration of DMSO was 0.1%. Then,
cells were washed with PBS+ and serum-free medium
(SFM). Subsequently, cells were stimulated for 4 h with
hCG in SFM supplemented by 0.1% BSA. The medium
was collected for progesterone determination and the cells
were either dissolved in lysis buffer containing the prote-
ase inhibitor phenylmethylsulfonyl fluoride for protein
determination or prepared for other biochemical assays.
Cell viability assay
Cell viability was evaluated by the MTT proliferation
assay. MTT (5 mg/mL) was sterilized by filtration
through a 0.22 μM Millipore® filter and stored at 4°C.
Cells were plated at a density of 1.5×104 per well in 96-
well plates. After 24 h of incubation in the different
doses of MBP, 25 μl MTT was added to each well and
the cells were incubated for 4 h at 37°C. Non-treated
cells served as a negative control. The medium was
removed and 150 μl DMSO was added to each well and
oscillation was then performed for 10 min. The absor-
bance was determined at 490 nm. Results were presented
as percentage of the values measured in untreated
control cells.
Detection of progesterone
Progesterone in the medium was measured with I125-
pregesterone Coat-A-Count radioimmunoassay (RIA) kits
(Beijing North Institute of Biological Technology, China).
The minimum detectable concentration of progesterone
was 0.2 ng/mL. Inter-and intra-assay coefficients of vari-
ation were <10% and <15%, respectively. Cellular protein
levels were quantified using the BCA Kit (Beyotime
Institute of Biotechnology, Shanghai, China).
Quantitative real-time RT-PCR assay
Cells were plated at a density of 1 × 106 per well in 6-
well plates (Corning®Gorilla® Glass) with a volume of
3 mL per well and treated with MBP for 24 h, then stimu-
lated by hCG for 4 h. To measure the level of StAR mRNA
expression in MLTC-1 cells, total RNA was isolated using
Tripure Isolation Reagent. Total RNA (2 μg) was convertedto cDNA using PrimeScipt® RT Master Mix Perfect Real
Time Kit from Takara Biotechnology Co. Ltd (Dalian,
China). The resulting cDNA was used as a template for
real-time reverse transcription-polymerase chain reaction
(RT-PCR). The primers used were as follows: rodent
glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
sense 5’-GCCGGTGCTGAGTATGTC-3’ and antisense 5’-
CTTCTGGGTGGCAGTGAT-3′ spanning from 311 to
601, 291 bp; StAR, sense 5’-ATCATTGTGCCGACTTCC
CTAC-3′ and antisense 5’-ACCAGGTTAGCCTCAGTA
TTAGA-3’ spanning from 1386 to 1671, 286 bp. The
values were normalized using GAPDH as the internal
standard. All reactions were performed on an ABI
PRISM 7900HT Sequence Detection System using
SYBR Green PCR.
Protein isolation and western blot analysis
Concentrations of protein were quantified by the BCA
protein assay kit. Samples were used immediately or
stored in aliquots at −80°C until use. Extracts were
thawed only one time prior to use. Total proteins (80 μg)
solubilized in the sample buffer (25 mM Tris, pH 6.8, 1%
SDS [w/v], 5% beta-mercaptoethanol [v/v], 1 mM ethylene
diaminetetraacetic acid [EDTA], 4% glycerol, and 0.01%
bromophenol blue) were loaded onto a 12.3% SDS (w/v)
polyacrylamide gel electrophoresis (SDS PAGE; Mini-
Protean II, Bio-Rad Laboratories, Hercules, CA). SDS-
PAGE was performed at 60 V for 1 h and then at 100 V
for 2 h using standard running buffer (24 mM Tris, 0.19
M glycine, and 0.5% SDS, pH 8.3) as described previously
with minor modifications (Manna et al., 2004). The pro-
teins were then electrophoretically transferred to a
polyvinyldiene difluoride membrane (PVDF, Bio-Rad,
Hercules, CA) at 0.15A for 1–1.5 h at room temperature
with transfer buffer (20 mMTris, 150 mM glycine, 10%
methanol, and 0.01% SDS). The membranes were incu-
bated in blocking buffer (Tris-buffered saline, TBS
containing 0.2% Tween-20 and 5% non-fat milk) for 2 h at
room temperature, followed by incubation overnight at
4°C with specific mouse polyclonal antibodies for StAR
(Santa Cruz, CA, USA, 1:100 dilution), P450scc (Beijing
Biosynthesis Biotechnology Co., LTD, 1:500 dilution), 3
beta-HSD (Santa Cruz, CA, USA, 1:200 dilution), SF-1
(Santa Cruz sc-28740x, 1:100 dilution), DAX-1 (Santa
Cruz sc-13064, 1:100 dilution), C/EBP-beta (Santa Cruz
sc-150x, 1:100 dilution), or GATA-4 (Santa Cruz sc-1237x,
1:100 dilution). The membranes were washed three times
(10 min each) in TBS buffer and incubated for 1 h at room
temperature followed by incubation with goat anti-mouse,
goat anti-rabbit or rabbit anti-goat secondary antibody
conjugated with horseradish peroxidase at 1:1000, and the
specific signals were detected by chemiluminescence with
ECL Western blotting detection kit (Amersham Life
Science Limited) after a final 1–1.5 h wash in TBST. After
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bands were quantified. Densitometry was performed
using ImageJ software. All blots were normalized to
GAPDH and expressed as fold change over the control
group.
Electrophoretic mobility shift assay
Oligonucleotide sequences of SF-1, GATA-4, and C/
EBP-beta EMSA were used: SF-1 (−56/-30 bp), 5’Bio-
TGATGATGCACAGCCTTCCACGGGAAG-3’; GATA-
4 (−76/-51 bp), 5’Bio-GATGACTTTTTTATCTCAAGT
GATGA-3’; C/EBP-beta (−125/-100 bp), 5’Bio-ACTGCA
GGATGAGGCAATCATTCCAT-3’. Electrophoretic mo-
bility shift assay (EMSA) was performed for analysis of
DNA-binding of SF-1 according to the manufacturer’s
protocol using the Pierce Light Shift Chemiluminescent
EMSA kit. Briefly, 10 μg protein nuclear extracts were
obtained by Nuclear and Cytoplasmic Protein Extraction
Kit. Nuclear extracts from nontreated or MBP-treated
(24 h) MLTC-1 cells were incubated with double-
stranded binding fragments at room temperature for
20 min. After incubation, samples were separated on a
0.5×TBE SDS-PAGE minigel and electrophoretically
transferred to a nylon membrane. After exposed to x-
ray films for 1–5 min, relative intensity of the shifted
band was normalized by the value from the control
group. EMSA for measuring DNA-binding of GATA-4,
and C/EBP-beta was conducted in the same manner as
that applied to the SF-1 DNA-binding assay. Densi-Figure 1 Analysis of cell viability and production of progesterone in M
concentrations of MBP (10(−9), 10(−8), 10(−7), or 10(−6) M) or DMSO as co
determined using MTT assay. Results were presented as percentage of the
represented as mean ± S.E. from three separate experiments in which treat
difference was found between the treatment groups and the control grou
(−8), 10(−7), or 10(−6) M) or DMSO as control for 24 h, and then the mediu
for 4 h. Each data point represents as mean ± S.E. from at least three separ
quadruplicates. * indicates significant difference when the values were comtometry for shifted bands was determined by ImageJ
software.
Statistics analysis
Data were expressed as mean ± S.E. for all experiments
done three times in quadruplicate for each treatment.
Statistical differences between the treatments and the
control were determined by one-way analysis of variance
(ANOVA) and least significant difference (LSD) multiple
comparison procedure. For all comparisons P<0.05 was
considered significant.
Results
Effects of MBP on cell viability
Cytotoxicity was not observed following treatments with
MBP (10(−9), 10(−8), 10(−7), or 10(−6) M) for 24 h in
MLTC-1 cells. Therefore, these doses were selected in
the following test. The cell viability result is shown in
Figure 1A.
MBP increased progesterone production
According to the cell viability results, MLTC-1 cells were
treated with various doses of MBP for 24 h and then
stimulated by hCG (0.1 U/ml) for 4 h in vitro. Compared
with control group treated by DMSO, production of
progesterone was increased after MBP treatments in
dose-dependent manner with the increase of 29.76% and
31.72% in 10(−7) and 10(−6) M of MBP, respectively
(Figure 1B).BP treated MLTC-1 cells. (A) Cells were cultured with various
ntrol for 24 h. At the end of incubation, the cell viability was
values measured in untreated control cells. Each data point
ments were performed in quadruplicate. No statistically significant
p. (B) Cells were treated with various concentrations of MBP (10(−9), 10
m was changed to SFM and cells were stimulated with hCG (0.1 U/ml)
ate experiments in which treatments were performed in
pared with the control (P< 0.05).
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As we found low-dose MBP-stimulated steroidogenesis,
we further explored the mechanisms underlying the
increase of progesterone production. We examined the
expression of genes involved in steroid biosynthesis
pathway including StAR, cytochrome P450scc and 3 beta-
hydroxy-steroid dehydrogenase (3 beta-HSD) [19,20,27].
Results showed that levels of StAR mRNA and protein
were unchanged in both 10(−9) and 10(−8) M but
increased markedly after exposure to10 (−7) and 10(−6)
M MBP. Compared with control group, MBP increased
1.28-fold and 1.55-fold of mRNA in 10(−7) and 10(−6) M
groups, respectively (Figure 2A). Also, MBP increased
1.97-fold and 4.17-fold of protein levels in 10(−7) and 10
(−6) M groups, respectively (Figure 2B). However, protein
levels of P450scc and 3 beta-HSD were unchanged after
MBP exposure (Figure 2C, 2D and 2E). Therefore, ourFigure 2 Expression of StAR, P450scc and 3 beta-HSD in MBP treated
10(−6)M) or DMSO as control for 24 h and then stimulated with hCG for 4
RT-PCR using GAPDH as housekeeping gene. (B) The panel shows a repres
corresponding GAPDH. The figure represents as mean ± S.E. of StAR protei
data point was normalized to the control (DMSO) and represents as mean
difference when the values were compared with the control (P< 0.05). (C-E
and 3 beta-HSD protein expression corrected by corresponding GAPDH. Th
integrated optical density corrected by corresponding GAPDH. Each data p
mean ± S.E. from three independent experiments.next study focused on the regulation of StAR expression
after MBP exposure.
MBP increased DNA-binding of SF-1, GATA-4 and C/EBP-
beta with promoter regions of StAR
Multiple lines of evidence demonstrated the involve-
ments of several transcription factors including SF-1,
GATA-4 and C/EBP-beta in StAR expression and ste-
roidogenesis [26,28]. We further investigated whether
MBP-induced StAR expression alteration were resulted
from these transcription factors. Interestingly, EMSA
results revealed that DNA-binding of SF-1, GATA-4 and
C/EBP-beta with promoter regions of StAR was elevated
in10(−6) M MBP group (Figure 3A, 3B and 3C), indi-
cating SF-1, GATA-4 and C/EBP-beta might play an
important role in low-dose MBP stimulated StAR
expression.MLTC-1 cells. Cells were treated with MBP (10(−9), 10(−8), 10(−7), or
h. (A) StAR mRNA levels were determined by quantitative real-time
entative western blot analysis of StAR protein expression corrected by
n integrated optical density corrected by corresponding GAPDH. Each
± S.E. from three independent experiments. * indicates significant
) The panel shows a representative western blot analysis of P450scc
e figure represents as mean ± S.E. of P450scc and 3 beta-HSD protein
oint was normalized to the control (DMSO) and represents as
Figure 3 Examination of transcription factors binding in MBP treated MLTC-1 cells. (A-C) The binding of SF-1, GATA-4, and C/EBP-beta
with the StAR promoter regions after MBP treatment for 24 h, and then stimulated with hCG for 4 h. It was evaluated by an EMSA described in
the “Materials and Methods” section. Lane 1: blank (only labelled probe); Lane 2: control-without MBP treatment (labelled probe and nuclear
protein); Lane 3: treated with 10(−9) M MBP for 24 h (labelled probe and nuclear protein); Lane 4: treated with10 (−6) M MBP for 24 h (labelled
probe and nuclear protein); Lane 5: positive control (unlabeled probe, labelled probe, and nuclear protein). The DNA-binding of SF-1, GATA-4 and
C/EBP-beta with the StAR promoter regions was determined by quantified bar graph using control without MBP treatments. * indicates
significant difference when the values were compared with control (P<0.05).
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C/EBP-beta and decrease of protein levels of DAX-1
In order to further validate the role of SF-1, GATA-4
and C/EBP-beta, aside from DNA-binding, protein levels
of SF-1, GATA-4, and C/EBP-beta were examined using
western blot. Protein levels of SF-1, GATA-4 and C/
EBP-beta were increased after low-dose MBP treatment
(Figure 4). We also analyzed the protein levels of DAX-1
(a negative factor of SF-1) after MBP treatment. We
found that DAX-1 protein levels were significantly
decreased after MBP exposure (Figure 4).
Discussion
PAEs are considered to be one of endocrine disrupting
chemicals (EDCs) [29,30]. From a number of researches,
consistent toxicological evidence of adverse reproductive
effects of DBP and other phthalates could be found at
relatively high doses such as 50, 100, 200, 400 and 800 μM
of MBP [31]. In recently published paper, Vandenberg
et al. (2012) reviewed mechanistic data for low-dose
effects of EDCs, and claimed that EDCs can have effectsat low doses that are not predicted by effects at higher
doses [32]. Indeed, effects of low-dose chemicals, or called
hormesis, have received considerable attention over the
past several years [33,34]. In the present study, low-dose
effects of MBP on steroidogenesis were examined in vitro
using MLTC-1 cells as a model. Results demonstrated that
steroidogenesis was increased after 10(−7) and 10(−6) M
MBP treatments, suggesting that MBP exhibited stimu-
lation effects on steroidogenesis at low doses in MLTC-1
cells. This finding is consistent with previous reports
(Fan J, et al. 2010. Endocrinology 151, 3348–62)[18]. In
order to further explore the underlying mechanisms, we
examined expression of genes involved in steroid biosyn-
thesis pathway, and found mRNA and protein of StAR, a
key and rate-limiting protein in steroidogenesis, were
elevated by MBP in the similar manner, suggesting that
MBP-induced increase of steroidogenesis may result from
stimulation of StAR protein expression.
It is well known that StAR expression is modulated by
many transcription factors. Previous studies showed that
SF-1, GATA-4 and C/EBP-beta may be closely related to
Figure 4 Expression of transcription factors protein in MBP treated MLTC-1 cells. Cells were treated with MBP (10(−9), 10(−8), 10(−7), or
10(−6) M) or DMSO as control for 24 h, and then stimulated with hCG for 4 h. The panel shows a representative western blot analysis of SF-1,
GATA-4, C/EBP-beta and DAX-1 protein expression corrected by corresponding GAPDH. SF-1, GATA-4, C/EBP-beta and DAX-1 protein expressions
were determined by quantified bar graph using GAPDH. * indicates significant difference when the values were compared with the control
(P< 0.05).
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these factors played important roles in regulation of
StAR expression [36]. Therefore, transcription factors
may be involved in the alteration of StAR mRNA and
protein levels after MBP treatments.
SF-1 is a nuclear receptor that plays multiple roles
throughout the hypothalamic-pituitary-steroidogenic
organ axis, which has been characterized as a master
regulator of steroidogenesis and can function at StAR
gene promoter regions to control StAR transcription
[37-39]. Also, it has been found that mutation in the SF-
1 binding sites resulted in decreased StAR expression in
in vitro reporter gene assays [24,40], and it has been
reported that SF-1 knockout mice did not express StAR
mRNA, indicating SF-1 is required for StAR gene ex-
pression [41]. Thus, SF-1 may play an important role in
positive regulation of StAR expression. Previous studies
have shown that bind sites of SF-1 to StAR promoters in
rat, humans, porcine, ovine and mouse, were at −493/-
483, -456/-445, -143/-132, -106/-97, -764/-754 and −46/-
40 [24,42-44]. In our study, we detected DNA-binding of
SF-1 at −46/-40 of StAR promoters. We found that DNA-
binding of SF-1 was increased by MBP treatment at 10
(−6) M (Figure 3A). At the same time, SF-1 protein
expression was elevated after exposure to MBP (Figure 4).Moreover, in vitro studies showed that DAX-1 could
inhibit SF-1-mediated transactivation [45]. Therefore, to
further validate the SF-1 role in MBP-stimulated StAR
expression, DAX-1 protein levels were next analyzed by
western blot. We found that DAX-1 protein expression
was lowed in dose-dependent manner (Figure 4). Collec-
tively, increased progesterone production by exposure to
MBP may be regulated by SF-1 and subsequently affecting
StAR expression. Thus, it is likely that one of the
important mechanisms of low-dose MBP-induced sti-
mulation of steroidogenesis may be mediated by SF-1
regulation on StAR.
GATA-4, a member of GATA group of conserved
transcriptional regulators with a highly conserved zinc
finger DNA-binding domain, is expressed in steroidogenic
cells [46,47], and regulates gene expression, differentiation
and cell proliferation by binding to the consensus DNA
sequence [48]. At the same time, GATA-4 is important
for activation of StAR transcription by binding to the
proximal cis-elements in the StAR promoter [49].
Previous studies revealed a GATA binding element at
position −66/−61 in the mouse StAR promoter [25,50].
In this study, we found that DNA-binding of GATA-4 was
increased at 10(−6) M after MBP treatments (Figure 3B).
Also, GATA-4 protein expression was increased in dose-
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may also undertake in steroidogenesis after low-dose MBP
treatments.
C/EBP-beta presents in steroidogenic cells including
Leydig and granulosa cells [51], which plays a vital role
in LH-regulated Leydig cell differentiation and function.
C/EBP-beta is regulated by hCG/LH [52]. It was repor-
ted that C/EBP-beta represented the ability of binding
with StAR promoter regions in rats [36,53]. Moreover,
related study indicates C/EBP-beta can positively regu-
late basal StAR gene expression [54]. In the present
study, oligonucleotide sequences at −117/-108 were
selected for C/EBP-beta binding with StAR promoters
[23]. We found that C/EBP-beta could bind with StAR
promoter regions and DNA-binding of C/EBP-beta was
increased after MBP exposure (Figure 3C). These find-
ings agree with previous report in which 8-Br-cAMP
stimulation also altered this molecular event [36]. Also,
C/EBP-beta protein expression was also increased afterFigure 5 Schematic presentation of low-dose MBP-stimulated progeslow-dose MBP treatments (Figure 4). Thus, aside from
SF-1 and GATA-4, the increased DNA-binding and
expressions of C/EBP-beta may also result in the eleva-
tion of StAR protein and production of progesterone by
low-dose MBP treatments.
Conclusions
In summary, we firstly delineated that regulation of
StAR by transcription factors including SF-1, GATA-4
and C/EBP-beta maybe critical mechanisms involved in
low-dose MBP-stimulated steroidogenesis. Low-dose MBP
may alter DNA-binding of SF-1, GATA-4, C/EBP-beta
and expression of SF-1, GATA-4, C/EBP-beta protein, and
then stimulates transcription and expression of StAR.
Besides, MBP-induced downexpression of DAX-1 which
is the negative factor of SF-1 may also be involved in this
process. Following these molecule events, steroid pro-
duction was stimulated at last (Figure 5). Herein, we
provide a new horizon in low-dose effects associated withterone synthesis in MLTC-1 cells.
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promote further study on providing deep insight into the
initial molecular actions which influence SF-1, GATA-4,
and C/EBP-beta in PAEs-stimulated steroidogenesis.
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